White Paper

Early Planning To De-Risk Development: Nonclinical Strategy And Study Design

Source: Premier Consulting
GettyImages-655801842 data

Having completed drug discovery and identified your lead asset, it's time to commence IND-enabling activities, bringing you closer to the clinical deployment stage. Because only a fraction of nonclinical lead assets progresses to the clinic, the significance of your nonclinical program cannot be overstated. It is pivotal in determining whether your program advances to Phase 1 and influences the timeline for reaching that milestone.

Although you may not have control over all variables, focusing on the ones within your control can help mitigate avoidable risks and maximize the likelihood of your product reaching the clinical stage. Implementing effective strategies in nonclinical development involves the strategic design and meticulous planning to identify appropriate studies and create an optimized roadmap that minimizes risk during critical early-stage milestones. By prioritizing intelligent decision-making and proactive planning, you can enhance the chances of success for your product in the nonclinical phase.

Whether you are a researcher, scientist, or industry professional, these resources will equip you with the knowledge and tools to successfully navigate the nonclinical development process.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene